Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.49 |
| ▸ | PNMT | P11086 | 6/20 | 0.49 |
| ▸ | CD44 | P16070 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011236 | 1.00 | ASIC3 (0.49) | ASIC3PNMTCD44MAOBSYK | |
| SCHEMBL1010747 | 0.94 | ASIC3 (0.56) | ASIC3PNMTCD44MAOBSYK | |
| SCHEMBL21557598 | 0.87 | HTR1A (0.47) | ASIC3SYKHTR1AHTR7 | |
| SCHEMBL4307271 | 0.83 | ASIC3 (0.52) | ASIC3PNMTCD44MAOBSYK | |
| SCHEMBL4309186 | 0.81 | SLC6A2 (0.50) | ASIC3PNMTCD44MAOBADRA2A | |
| SCHEMBL18554758 | 0.81 | ASIC3 (0.48) | ASIC3PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL4305543 | 0.81 | ASIC3 (0.51) | ASIC3PNMTSYKADRA2AADRA2B | |
| SCHEMBL23351094 | 0.79 | CYP11B1 (0.47) | HTR1AHTR7 | |
| SCHEMBL4024459 | 0.79 | CYP11B1 (0.51) | HTR1AHTR7 | |
| SCHEMBL4025451 | 0.78 | CYP11B1 (0.50) | HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | LDLR, PCSK9, CETP | ASIC3 4460/4885PNMT 4172/4885CD44 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.